Journal of Neuro-Oncology

, Volume 105, Issue 3, pp 591–600

IDH mutation status impact on in vivo hypoxia biomarkers expression: new insights from a clinical, nuclear imaging and immunohistochemical study in 33 glioma patients

  • Philippe Metellus
  • Carole Colin
  • David Taieb
  • Eric Guedj
  • Isabelle Nanni-Metellus
  • Andre Maues de Paula
  • Cécile Colavolpe
  • Stephane Fuentes
  • Henry Dufour
  • Marylin Barrie
  • Olivier Chinot
  • L’Houcine Ouafik
  • Dominique Figarella-Branger
CLINICAL STUDY – PATIENT STUDY

DOI: 10.1007/s11060-011-0625-2

Cite this article as:
Metellus, P., Colin, C., Taieb, D. et al. J Neurooncol (2011) 105: 591. doi:10.1007/s11060-011-0625-2

Abstract

Mutations in the gene encoding isocitrate dehydrogenase enzyme isoforms 1 (IDH1) and 2 (IDH2) have recently been identified in a large proportion of glial tumors of the CNS, but their mechanistic role in tumor development remains unclear. Here, we assessed the actual impact of IDH1 and IDH2 mutations in patients harboring WHO grade II and III gliomas. We sequenced IDH1 at codon 132 and IDH2 at codon 172 in 33 patients with WHO grade II and III gliomas who benefited from a preoperative 18F-FDG positron emission tomography (PET). Immunohistochemical expression of Hypoxia Inducible Factor-1alpha (HIF-1α), Carbonic Anhydrase IX (CAIX), Glucose Transporter 1 (GLUT1) and Caspase 3 active form (CASP3) along with the R132HIDH1 mutation was assessed in all cases as well as 1p/19q deletion status and p53 expression. HIF-1α expression was found in 15% of IDH-mutated compared to 7.7% of IDH-nonmutated tumors (P = 0.954). Also, GLUT-1 positive staining was found in 5% of IDH-mutated and in 7.1% of IDH-nonmutated tumors (P = 0.794). Finally, CA-IX expression was found in 15% of IDH-mutated and in 7.7% of IDH-nonmutated tumors (P = 0.484). The combined expression of these three hypoxic markers was found in two WHO grade III tumors, one of which was IDH-mutated whereas the other was IDH-nonmutated (P = 0.794). In IDH-mutated tumors, the median SUVmax ratio was 2.24 versus 2.15 in IDH-nonmutated tumors (P = 0.775). Together, these data question the actual relationship between IDH mutation status and in vivo hypoxic biomarkers expression in WHO grade II and III gliomas.

Keywords

Active caspase 3 Carbonic anhydrase IX Glucose transporter 1 Isocitrate dehydrogenase-1(IDH1) Hypoxia-inducible factor 1 

Copyright information

© Springer Science+Business Media, LLC. 2011

Authors and Affiliations

  • Philippe Metellus
    • 1
    • 2
    • 3
    • 8
  • Carole Colin
    • 2
    • 3
  • David Taieb
    • 4
  • Eric Guedj
    • 4
  • Isabelle Nanni-Metellus
    • 5
  • Andre Maues de Paula
    • 6
  • Cécile Colavolpe
    • 6
  • Stephane Fuentes
    • 1
  • Henry Dufour
    • 1
  • Marylin Barrie
    • 7
  • Olivier Chinot
    • 2
    • 3
    • 7
  • L’Houcine Ouafik
    • 2
    • 3
    • 5
  • Dominique Figarella-Branger
    • 2
    • 3
    • 6
  1. 1.Hôpital de la Timone, Service de NeurochirurgieAssistance Publique-Hôpitaux de MarseilleMarseilleFrance
  2. 2.INSERM, UMR 911MarseilleFrance
  3. 3.Faculté de MédecineAix-Marseille UniversitéMarseilleFrance
  4. 4.Hôpital de la Timone, Service Central de Biophysique et Médecine nucléaireAssistance Publique-Hôpitaux de MarseilleMarseilleFrance
  5. 5.Laboratoire de Transfert D’oncologie BiologiqueAP-HMMarseilleFrance
  6. 6.Hôpital de la Timone, Service d’Anatomie Pathologique et de NeuropathologieAssistance Publique-Hôpitaux de MarseilleMarseilleFrance
  7. 7.Hôpital de la Timone, Unité de NeurooncologieAssistance Publique-Hôpitaux de MarseilleMarseilleFrance
  8. 8.Service de NeurochirurgieHôpital de la TIMONECedex MarseilleFrance

Personalised recommendations